Free Trial
NASDAQ:INM

InMed Pharmaceuticals (INM) Stock Price, News & Analysis

InMed Pharmaceuticals logo
$2.12 +0.04 (+1.68%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About InMed Pharmaceuticals Stock (NASDAQ:INM)

Key Stats

Today's Range
$2.09
$2.13
50-Day Range
$2.06
$4.22
52-Week Range
$1.99
$15.70
Volume
20,320 shs
Average Volume
227,349 shs
Market Capitalization
$2.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Remove Ads

InMed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

INM MarketRank™: 

InMed Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for InMed Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InMed Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about InMed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of InMed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    InMed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    InMed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of InMed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    InMed Pharmaceuticals has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for InMed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for INM on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.85% of the stock of InMed Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 20.12% of the stock of InMed Pharmaceuticals is held by institutions.

  • Read more about InMed Pharmaceuticals' insider trading history.
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Stock News Headlines

BITCOIN
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this...
See More Headlines

INM Stock Analysis - Frequently Asked Questions

InMed Pharmaceuticals' stock was trading at $4.74 at the start of the year. Since then, INM shares have decreased by 56.1% and is now trading at $2.08.
View the best growth stocks for 2025 here
.

InMed Pharmaceuticals Inc. (NASDAQ:INM) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($3.64) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 90.74% and a negative net margin of 163.75%.

Shares of InMed Pharmaceuticals reverse split on the morning of Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL).

Company Calendar

Last Earnings
2/12/2025
Today
4/03/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,680,000.00
Net Margins
-163.75%
Pretax Margin
-163.58%

Debt

Sales & Book Value

Annual Sales
$4.83 million
Price / Cash Flow
N/A
Book Value
$5.12 per share
Price / Book
0.41

Miscellaneous

Free Float
711,000
Market Cap
$2.51 million
Optionable
Not Optionable
Beta
0.18
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:INM) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners